Blood transfusion is a remarkably safe, routine clinical procedure. However
, the need for sophisticated blood processing, storage and cross-matching,
coupled with increasing concerns about the safety of blood products, has fu
elled the search for safe and efficacious substitutes. Candidate materials
based on modified haemoglobin (including recombinant molecules) or highly i
nert, respiratory gas-dissolving perfluorinated liquids (perfluorochemicals
) have been developed. The latter are immiscible in aqueous systems and mus
t, therefore, be injected as emulsions. Second-generation perfluorochemical
emulsions are available and in clinical trials as temporary intravascular
oxygen carriers during surgery, thereby reducing patient exposure to donor
blood. One commercial product is currently under Phase III clinical evaluat
ion, with regulatory approval expected within 1-2 years. Other biomedical a
pplications for perfluorochemicals and their emulsions include their use as
pump-priming fluids for cardiopulmonary bypass, lung ventilation fluids, a
nti-cancer agents, organ perfusates and cell culture media supplements, dia
gnostic imaging agents and ophthalmologic tools. Novel applications for per
fluorochemicals as immunomodulating agents are also being explored. (C) 199
9 Harcourt Publishers Ltd.